CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 90 enrolled
Drug / intervention
Budesonidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00860938
NCT00860938Phase 4Completed
CompareCT.gov

Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD)

Cantonal Hosptal, Baselland·interventional·Posted Mar 13, 2009·Updated Jul 23, 2019

In Brief

A Phase 4 clinical trial evaluating Budesonide for COPD. Completed, enrolled 90 participants across 1 site.

Detailed Summary

Study purpose is to evaluate if subjects with chronic obstructive pulmonary disease (COPD) are more likely to be responsive to additional inhaled corticosteroids if they have a positive response to hyperosmolar challenge with mannitol than if their response is negative.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesSwitzerland
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2009
Enrollment StartApr 1, 2007
Primary CompletionAug 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.3 years ago

Interventions

Budesonidedrug

After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo